Menu
Search Close

News

Final Results for the year ended 30 April 2010

14th July 2010

Scancell Holdings plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces its final results for the year ended 30 April 2010.

Highlights:

  • Strong progress in the development of the Company’s lead therapeutic melanoma vaccine SCIB1
  • Successful fundraising of £2.54 million (gross) during 2010
  • Loss before tax for the year of £1.80 million (2009: £0.8 million)
  • Cash at year end of £2.83 million
  • Since the year end the Company commenced Phase I/IIa clinical trials in humans for SCIB1

The Directors of the issuer accept responsibility for this announcement.

For further information contact:

Professor Lindy Durrant, (CEO)  -  Scancell Holdings Plc:

  • +44 (0)207 245 1100

John Bick/Kirsty Corcoran  -  Hansard Communications

  • +44 (0)207 245 1100
  • +44 (0)7872 061 007

Ross Andrews/Tom Rowley  -  Zeus Capital

  • +44 (0)161 831 1512

View the full document

Webcasts, Interviews and Media Coverage

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Tue, 20 Aug 2019 06:05:00

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00